Bupivacaine controlled release - DURECT Corporation
Alternative Names: Bupivacaine extended release - DURECT Corporation; Bupivacaine solution - DURECT Corporation; Optesia; POSIDUR; POSIMIR; SABER®-bupivacaineLatest Information Update: 29 Sep 2022
At a glance
- Originator DURECT Corporation
- Developer DURECT Corporation; Takeda Pharmaceuticals International GmbH
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Postoperative pain
Highest Development Phases
- Marketed Postoperative pain